Visual Outcomes, Quality of Vision, Patient Satisfaction and Spectacle Independence After Bilateral Implantation of the Synergy™ Intraocular Lens

Abstract

Purpose

To evaluate vision, visual quality, patient satisfaction and spectacle independence after bilateral implantation of the TECNIS Synergy™ intraocular lens.

Setting

Two clinical practices in the USA.

Design

Ambispective unmasked non-randomized clinical trial.

Methods

Patients with a history of uneventful bilateral femtosecond laser assisted cataract surgery with the study IOL implanted, targeted for emmetropia, at least 3 months prior to the study visit were enrolled. Monocular and binocular visual acuity (VA) were measured at distance, intermediate and near, along with binocular mesopic VA. Low contrast binocular VA and reading speed in mesopic and photopic conditions were also measured. Patient satisfaction, spectacle independence, visual symptoms, and functional vision questionnaires were completed.

Results

Results from 52 subjects were available for analysis. Mean binocular unaided visual acuity was ~0.1 logMAR (20/20) from distance to 33 cm, with 81% of subjects having 0.2 logMAR (20/25) vision or better at all test distances and 92% reporting never needing glasses at any distance. Average reading speed at 40 cm was only 10 words/minute slower in dim light (p = 0.03). Mesopic and low contrast acuity appeared good. Halos were the most frequent and bothersome visual disturbances, with the greatest effect on driving at night. Eighty-eight percent of subjects reported being “completely” or “mostly” satisfied with their overall unaided vision.

Conclusion

This hybrid technology IOL provided a range of binocular visual acuity from distance to 33 cm and good functional vision, even in dim light. Patients should be advised of the likelihood of visual disturbances, particularly halos.

Keywords:

• synergy
• multifocal IOL
• diffractive
• hybrid technology

Disclosure

Joaquin O. De Rojas is a consultant for Advanced Euclidean Solutions, Johnson & Johnson Vision, Oculus Biologics, Carl Zeiss Meditec and Sun Pharmaceuticals. Helga Sandoval reports grants paid to institution from Johnson and Johnson Vision and royalties from TissueTech. Richard Potvin is a consultant to and reports personal fees from Alcon, Hoya, and Carl Zeiss Meditec. Kerry D. Solomon is a consultant for Alcon Laboratories, Allergan, Aquesys, Bausch and Lomb, Clarvista Medical, Glaukos, Icon Bioscience, Imprimis, Integrity Digital Solutions, Johnson & Johnson Vision, Kala Pharmaceuticals, Lenstec, Mati Therapeutics, Octane Visionary VC Fund, Ocuhub, Omeros Corporation, Pogotec, PRN, Tearlab, Versuant. The authors report no other conflicts of interest in this work.

Additional information

Funding

The study was supported by an investigator-initiated study grant from J&J Vision, USA (IIT: JD-1262).